Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
238lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
45 lessons
6mPeptidesBeginner
Should You Cycle NAD+? The Complete Guide to NAD+ Protocols
Daily NAD+ supplementation can plateau due to NAMPT downregulation. Here's how to cycle NMN and NR for sustained results.
9mResearchAdvanced
Retatrutide, Food Noise, and the Protein Floor: A Better Way to Keep Training on Track
When appetite drops, structure matters more. The people who keep the best retatrutide results are the ones who protect protein, training, and hydration before the scale gets noisy.
9mProtocolsIntermediate
MariTide Dosing Guide: Once-Monthly 140–420 mg Phase 2 Map
MariTide is the once-monthly obesity candidate people keep comparing to weekly GLP-1s. Here's the Phase 2 dosing map — 140 / 280 / 420 mg and the escalation arms that mattered for tolerability.
8mSafetyIntermediate
MariTide Beginner's Guide: What Maridebart Cafraglutide Is
MariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.
7mResearchAdvanced
Petrelintide Beginner's Guide: Roche/Zealand's Weekly Amylin Analog
Petrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.
8mProtocolsIntermediate
Petrelintide Dosing Guide: Once-Weekly Amylin Analog Titration
Petrelintide is the Roche/Zealand once-weekly amylin analog drawing GLP-1-level attention for tolerability. Here's the Phase 2 dosing pattern, results, and what to track.
9mProtocolsIntermediate
Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols
Amycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mProtocolsIntermediate
Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol
Searching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
8mResearchAdvanced
Eloralintide Weight Loss Results: Phase 2 Data and What to Watch in Phase 3
Phase 2 put eloralintide on the board with roughly 9–20% mean weight loss at 48 weeks. Here's the results breakdown — and the troubleshooting mindset for plateaus on any amylin or GLP-1 protocol.
8mProtocolsIntermediate
Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity
Survodutide is Boehringer's glucagon/GLP-1 dual agonist. Here's the dosing map from dose-finding through Phase 3 — weekly mg ranges, escalation logic, and what the weight-loss data showed.
7mProtocolsIntermediate
Mazdutide Dosing Guide: 4 mg and 6 mg Weekly Protocols Explained
Mazdutide is a once-weekly glucagon/GLP-1 dual agonist with clear Phase 3 dose anchors at 4 mg and 6 mg. Here's the dosing and results map searchers want.
8mResearchAdvanced
Tesamorelin and Waist-First Tracking: The Metrics That Matter Most
Tesamorelin is a body-composition tool, not a bathroom-scale trick. The best results show up when you track the right metrics from the start.
8mProtocolsIntermediate
Appetite Control on Peptides: What to Track Before the Scale Moves
Appetite control is useful only if it does not turn into under-eating. Track the right signals early so the scale does not hide the real tradeoffs.
9mResearchAdvanced
Retatrutide's FDA Watch Tightens After the Latest Obesity Trial Results
Retatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.
9mResearchAdvanced
Retatrutide Phase 3 Results: What They Mean for Appetite, Lean Mass, and Adherence
The real test for retatrutide is not whether it moves the scale. It is whether it makes the plan easier to follow without flattening training, energy, or lean mass.
9mPeptidesIntermediate
What Real-World GLP-1 Data Actually Tells Us About Safety and Results
Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
7mResearchAdvanced
Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows
Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
7mResearchAdvanced
Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means
31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mResearchAdvanced
Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard
New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
9mResearchAdvanced
GLP-1 for Weight Loss Without Diabetes: What the 2026 Systematic Review Found
You don't need to have diabetes to benefit from GLP-1 therapy. A comprehensive 2026 systematic review confirms what the peptide community has known for years — and the results are striking.
8mProtocolsIntermediate
MOTS-C Timing: When to Take It for Maximum Results
MOTS-C timing affects AMPK activation and metabolic benefits. Learn whether to take it fasted, how long to wait before eating, and how to optimize timing for AM or PM training schedules.
9mPeptidesIntermediate
MOTS-C and NAD+: Do They Work Together? (Complete Stacking Guide)
MOTS-C activates AMPK through mitochondrial signaling. NAD+ feeds the cellular energy substrate. Together, they hit the same system from two different angles — and the results are additive.
8mProtocolsIntermediate
Long-Term MOTS-C Use: Cycling, Receptor Sensitivity, and What to Expect
MOTS-C is mitochondria-encoded and activates AMPK through a pathway that's less prone to classic receptor downregulation. Here's how to structure long-term use for sustained results.
9mProtocolsIntermediate
KLOW Peptide Blend: What's In It, How to Use It, and When to Pin Separately
KLOW combines BPC-157, TB-500, and GHK-Cu into a single injection. Convenient for maintenance — but knowing when to switch to separate vials can make the difference between results and stalled recovery.
7mPeptidesIntermediate
MOTS-C Dosing Guide: Recommended Dose and How to Take It
MOTS-C is one of the most studied mitochondrial peptides for metabolic health and longevity. This guide covers dosing ranges, frequency, timing, stacking options, and what to track on protocol.
10mPeptidesIntermediate
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
9mPeptidesIntermediate
Ipamorelin and CJC-1295: The Complete Growth Hormone Peptide Stack Guide
Two peptides, one powerful GH pulse. Ipamorelin and CJC-1295 work together to mimic natural growth hormone release — here's the complete guide on why, how, and when to stack them.
8mPeptidesIntermediate
MOTS-C vs GHK-Cu for Muscle Building Over 50: Which Peptide Should You Choose?
Both MOTS-C and GHK-Cu are popular among serious lifters over 50 — but they work through completely different mechanisms. Here's how to choose, and why the best answer is often both.
9mResearchAdvanced
Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed
Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
10mPeptidesIntermediate
TB-500 and Cardiac Recovery: What the 2026 Human Trial Data Shows
TB-500 has moved from rodent models to human cardiac recovery trials. The 2026 data is early, but the mechanism and results are worth understanding — especially if you're using TB-500 for recovery.
11mPeptidesIntermediate
BPC-157: The Peptide That Regenerates Tissue—Science, Clinical Evidence, and Real Results
BPC-157 activates multiple tissue repair pathways simultaneously. Users report faster recovery from injury, improved gut healing, enhanced joint mobility—backed by published clinical data.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
8mStart hereBeginner
Retatrutide Beginner's Guide: Reconstitution, Dosing & Getting Started
New to retatrutide? This guide covers everything: how much BAC water to add, dose calculations for common vial sizes, starting doses, and titration schedules for safe, effective results.
8mPeptidesIntermediate
Retatrutide Phase 3 Results: What the Clinical Data Tells Us
New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
10mPeptidesIntermediate
Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial
Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
10mPeptidesIntermediate
Retatrutide: The Triple-Action Weight Loss Peptide Explained
Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.
10mPeptidesIntermediate
Peptide Research Breakthroughs in 2026: What Clinical Trials Show
2026 marks a pivotal year for peptide research. Here's what the latest clinical data reveals about the most promising peptide candidates and their real-world applications.
11mPeptidesIntermediate
Semaglutide for Weight Loss: Complete Guide to GLP-1 Peptide Therapy
Explore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.
10mPeptidesIntermediate
Tirzepatide: The Dual Agonist Revolution in Weight Loss
Discover why Tirzepatide's dual mechanism is producing record-breaking weight loss results in clinical trials.
11mProtocolsIntermediate
Peptide Stacking: How to Safely Combine Peptides for Better Results
Discover which peptides work synergistically together and how to stack them safely for enhanced benefits.
12mPeptidesIntermediate
Growth Hormone Peptides for Anti-Aging: The Science Explained
Discover the scientific foundation behind using GH peptides for anti-aging and longevity optimization.
8mProtocolsIntermediate
Peptide Cycling: When to Take Breaks and Why It Matters
Understand the science of peptide cycling and how to structure breaks for optimal long-term results.
10mResearchAdvanced
How to Read Peptide Research: Understanding Studies and Claims
Develop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.